Evolving approaches with interferon alfa in chronic myelogenous leukemia

Semin Hematol. 1993 Jul;30(3 Suppl 3):26-7.

Authors

E Morra¹, G Alimena, M Lazzarino, A M Liberati, E Montefusco, P Bernasconi, M Mancini, E Donti, S Merante, P Caricchi, et al.

Affiliation

¹ Institute of Hematology, University of Pavia, Italy.

PMID: 8235701

No abstract available

Publication types

Clinical Trial
Randomized Controlled Trial

MeSH terms

Adult
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Cytarabine / administration & dosage
Humans
Hydroxyurea / administration & dosage
Interferon alpha-2
Interferon-alpha / therapeutic use*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
Recombinant Proteins
Treatment Outcome

Substances

Interferon alpha-2
Interferon-alpha
Recombinant Proteins
Cytarabine
Hydroxyurea